HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation

Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...

詳細記述

保存先:
書誌詳細
出版年:Blood Adv
主要な著者: Peslak, Scott A., Khandros, Eugene, Huang, Peng, Lan, Xianjiang, Geronimo, Carly L., Grevet, Jeremy D., Abdulmalik, Osheiza, Zhang, Zhe, Giardine, Belinda M., Keller, Cheryl A., Shi, Junwei, Hardison, Ross C., Blobel, Gerd A.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2020
主題:
Red Cells, Iron, and Erythropoiesis
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/
https://ncbi.nlm.nih.gov/pubmed/32956454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料